- Increase in demand for biosimilars for the treatment of neutropenia and shift of pharmaceutical companies toward biosimilar drug development drive the growth of the global filgrastim market.
PORTLAND, Ore., Nov. 15, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, "Filgrastim Market by Drug Type (Biologic and Biosimilar), Indication (Chemotherapy-induced Neutropenia, Chronic Neutropenia and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021–2030." According to the report, the global filgrastim market generated $562.50 million in 2020, and is estimated to reach $745.90 million by 2030, witnessing a CAGR of 2.8% from 2021 to 2030.
Increase in demand for biosimilars for the treatment of neutropenia and shift of pharmaceutical companies toward biosimilar drug development drive the growth of the global filgrastim market. However, complexities in manufacturing biosimilar and rise in use of pegfilgrastim biologic hinder the market growth. On the other hand, surge in awareness and rise in investment in R&D activities create new opportunities in the coming years.
The Covid-19 pandemic made a disruptive impact on oncology clinical trials and treatments. There have been immediate and delayed consequences. As per the study carried out by the Cancer Research U.K. in July 2020, one in three cancer patients revealed that the pandemic impacted their treatments.
The hospital staff and resources were shifted to take care of Covid-infected patients. Moreover, trials for vaccines and potential treatments for Covid-19 have been conducted.
The reduction in recruitment for ongoing trials and delay in the launch of new oncology products would negatively impact the filgrastim market.
The biosimilar segment to continue its lead position during the forecast period
Based on drug type, the biosimilar segment accounted for the largest share in 2020, contributing to nearly three-fifths of the global filgrastim market, and is expected to continue its lead position during the forecast period. Moreover, this segment is projected to manifest the largest CAGR of 3.4% from 2021 to 2030. This is attributed to low cost, ease in availability in developing countries, ongoing R&D activities, and strong pipeline drugs. The research also analyzes the biologic segment.
The chemotherapy-induced neutropenia segment to maintain its dominant share during the forecast period
Based on indication, the chemotherapy induced neutropenia segment contributed to the largest share in 2020, accounted for nearly three-fifths of the global filgrastim market, and is estimated to maintain its dominant share during the forecast period. Moreover, this segment is expected to portray the highest CAGR of 3.0% from 2021 to 2030. This is due to the association of this side effect with life-threatening infections. Moreover, this may alter the schedule for chemotherapy and impact the early and long-term outcomes. The report also analyzes the segments including chronic neutropenia and others.
Europe, followed by North America, to continue its leadership status by 2030
Based on region, Europe, followed by North America, held the largest market share in 2020, accounting for around one-third of the global filgrastim market, and is projected to continue its leadership status by 2030. This is due to developed healthcare infrastructure, supportive reimbursement policies, increase in prevalence of infectious diseases, and availability of research grants and funding. However, Asia-Pacific is expected to register the fastest CAGR of 3.2% during the forecast period, owing to surge in the number of cancer patients, specifically in developing countries such as China and India.
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.